At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

The average one-year price target for Praxis Precision Medicines (NasdaqGS:PRAX) has been revised to $471.78 / share. This is ...

“Megan’s leadership has been a significant driver of Praxis’s success to date,” said Mr. Souza. “As COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined ...

Praxis Precision Medicines (PRAX) has drawn investor attention after recent share price moves, with the stock showing sharply different returns over the past year compared with its performance over ...

Praxis Management Group Inc. announces Georgia market expansion and continued growth driven by its strategic partnership with AT&T. Read on to find out more.